Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 1,116 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 112
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
재발성 악성 신경교종 또는 진행성 2차 뇌종양의 치료를 위한 디안히드로갈락티톨 및 그의 유사체 및 유도체의 용도
KR09.06.2016
1020157037286델 마 파마슈티컬스 인코포레이티드브라운, 데니스, 엠.
A61K 31/336
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
336
having three-membered rings, e.g. oxirane, fumagillin
재발성 신경교종 및 진행성 2차 뇌종양과 같은 악성 종양의 치료에 적합한 방법 및 조성물이 개시된다. 이들 방법은 디안히드로갈락티톨, 디안히드로갈락티톨의 유도체 또는 유사체, 디아세틸디안히드로갈락티톨, 또는 디아세틸디안히드로갈락티톨의 유도체 또는 유사체와 같은 헥시톨 유도체를 사용한다. 조성물은 이러한 헥시톨 유도체를 포함할 수 있다.

Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
CN18.03.2015
201380015319.5BROWN DENNISBACHA JEFFREY
A61K 31/35
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
KR16.11.2016
1020167030879델 마 파마슈티컬스 인코포레이티드바차, 제프리, 에이.
A61K 31/336
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
336
having three-membered rings, e.g. oxirane, fumagillin
디안하이드로갈락티톨의 사용은 비소세포 폐암종(NSCLC) 및 난소암의 치료를 위한 새로운 치료 양식을 제공한다. 디안하이드로갈락티톨은 DNA에 N 메틸화를 생성하는 알킬화제로서 작용한다. 디안하이드로갈락티톨은 암 줄기세포의 성장을 억제하는데 유효하고, 테모졸로미드, 시스플라틴, 및 티미딘 키나제 저해제에 대해 난치성인 종양에 대하여 활성이 있다; 이 약물은 MGMT 복구 메커니즘와 독립적으로 작용한다. 디안하이드로갈락티톨 다른 항신생물제와 함께 사용될 수 있으며, 부가적 또는 초부가적 효과를 가질 수 있다. 7

SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES
US14.01.2010
12282504Kolodney Michael S.
C12Q 1/68
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids

In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.


CHROMOGENIC MEDIUM FOR DETECTING CARIOGENIC BACTERIUM
JP12.02.2003
2001225137EIKEN CHEM CO LTDKOJIMA TEI
G01N 33/48
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
PROBLEM TO BE SOLVED: To provide a medium capable of separately detecting Streptococcus mutans and Streptococcus sobrinus of the mutans streptococcus group which are pathogen of dental caries by distinguishing the colonies thereof by the colors.

SOLUTION: A specimen obtained from the oral cavity is cultured in the chromogenic medium for detecting the cariogenic bacteria, containing a - glycosidase-colored substrate, a hydrogen peroxide-colored chromogen, a peroxidase and a sugar alcohol to separately detect the Streptococcus mutans and the Streptococcus sobrinus.

COPYRIGHT: (C)2003,JPO


Genetic marker for coronary artery disease
US27.07.2006
10565263AstraZeneca ABCarlsson Bjorn
C12Q 1/68
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids

The present invention describes a Coronary artery disease (CAD) susceptibility gene and the use of this gene in the development of novel therapies to treat CAD and in the diagnosis of susceptibility to CAD.


Systems and methods for sequencing by hybridization
US04.07.2006
10095363Brown University Research FoundationPreparata Franco P.
C07H 21/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
H
SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21
Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

The systems and methods described herein relate to nucleic acid probes comprising a pattern of universal and designate nucleotides (or analogs thereof), or ‘gapped’ probes, and the use of sets of gapped probes in sequencing by hybridization to determine the sequence of nucleic acid sequences. The inclusion of universal nucleotides in the probes allows for efficient and rapid sequencing of longer nucleotide sequences than can be sequenced using traditional probes. The systems and methods described herein also relate to apparatus for sequencing nucleic acids which include gapped probes, as well as computer systems capable of analyzing data generated using gapped probes in such apparatus.


Genetic marker for coronary artery disease
US29.06.2006
10565487AstraZeneca ABEdwards Richard
A61K 38/17
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans

The present invention describes a Coronary artery disease (CAD) susceptibility gene and the use of this gene in the development of novel therapies to treat CAD.


Lateral-flow measuring device and method for the measurement of analytes
EP22.03.2006
04021433ANALYTICON BIOTECHNOLOGIES AGMEISEGEIER BERNHARD DR
G01N 33/543
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
543
with an insoluble carrier for immobilising immunochemicals
Device (I), for detecting and/or determining the concentration of at least an analyte in a fluid medium, comprises rigid, reaction- and detection area (50), that is continuous along the carrier, and is formed by a oblong support (52) with a cover (54); and a fluid receiving element (60) arranged below the reaction- and detection area. Device (I), for detecting and/or determining the concentration of at least an analyte in a fluid medium (obtained from: a stripe shaped carrier (20) with two longitudinal folds (24) on which several repeating printed electrode are bound from at least one reference electrode (30) and from at least a working electrode (40); and a ligand that is suited for binding to a biological active specific binding molecule or the analyte), comprises rigid, reaction- and detection area (50), that is continuous along the carrier, and is formed by a oblong support (52) with a cover (54); and a fluid receiving element (60) arranged below the reaction- and detection area. Independent claims are also included for: (1) the preparation of (I); and (2) a method for detecting and determining the concentration of dissolved analytes in a fluid medium, using (I), comprises applying the fluid medium on the sample zone, allowing the analyte to interact, for a time period, with the ligand and/or biologically active specific binding molecule and/or catalytically active protein, applying a solution (comprising at least a reaction specific substrate for one or more catalytically active protein) on the sample zone, connecting (I) to an electrically measuring instrument and determining the reading from the signal obtained in the measuring instrument after incubating and calibrating a curve for the concentration of the respective analytes.

Methods For Identifying Compounds Capable of Modulating the Hydrolase Activity of Clca Protein
US25.09.2008
10590691LEPISTO MATTILepisto Matti
C12Q 1/34
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
34
involving hydrolase

Methods for identifying compounds capable of modulating the hydrolase activity of a CLCA protein include screening and computer modelling methods. The compounds, including antibodies, may be useful as therapeutic agents to treat a variety of diseases.


Results 1-10 of 1,116 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 112